Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Increased serum concentrations of growth differentiation factor-15 in children with acute rheumatic fever

  • Zerrin Karakuş-Epçaçan, Mehmet Gökhan Ramoğlu, Serdar Epçaçan
  • Journal:
    Cardiology in the Young / Volume 33 / Issue 5 / May 2023
    Published online by Cambridge University Press:
    19 May 2022, pp. 741-746
    • Article
      • You have access
      • Open access
    • PDF
    • HTML
    • Export citation
  • Aim:

    In this single-centre prospective study, we aimed to evaluate the role of growth differentiation factor-15 in children with acute rheumatic fever.

    Methods:

    The study group included 25 children with acute rheumatic fever, and the control group included 25 healthy children. In addition to routine laboratory tests used in the diagnosis and treatment of acute rheumatic fever, growth differentiation factor-15 levels of the study group (at the time of diagnosis and after the treatment) and the control group were assessed and compared.

    Results:

    The mean growth differentiation factor-15 level of the study group at the time of diagnosis (918.40 ± 605.65 pg/ml) was significantly higher than the mean post-treatment level (653.08 ± 330.92 pg/ml) (p = 0.015). Similarly, the mean growth differentiation factor-15 level of the study group at the time of diagnosis was significantly higher than the control group (p = 0.04). However, mean growth differentiation factor-15 levels were similar between the groups after the treatment. Growth differentiation factor-15 was positively correlated with both C-reactive protein (p < 0.001) and erythrocyte sedimentation rate (p = 0.001) at the time of diagnosis.

    Conclusion:

    Growth differentiation factor-15 levels are significantly increased in children with acute rheumatic fever at the time of diagnosis and return to similar levels with healthy children after treatment. Growth differentiation factor-15 is positively and significantly correlated with erythrocyte sedimentation rate and C-reactive protein at the time of diagnosis.

  • 64 - PARADOXICAL EMBOLISM AND STROKE

  • from PART VI: - NONINFLAMMATORY DISORDERS OF THE ARTERIAL WALL
  • Edited by Louis R. Caplan, Julien Bogousslavsky
  • Book:
    Uncommon Causes of Stroke
    Published online:
    06 January 2010
    Print publication:
    09 October 2008, pp 483-490

  • Summary

    Sweet's syndrome (SS), also referred to as acute febrile neutrophilic dermatosis, is characterized by a constellation of symptoms and findings: fever, neutrophilia, erythematous and tender skin lesions that typically show an upper dermal infiltrate of mature neutrophils, and prompt improvement of both symptoms and lesions after the initiation of treatment with systemic corticosteroids. Many instances are related to lympho proliferative disorders such as acute and chronic leukemia, acute and chronic lymphatic leukemia, hairy cell leukemia, polycythemia vera, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and other diseases of the hematopoietic system. Encephalitis and meningitis were the most common neurological manifestations. An elevated erythrocyte sedimentation rate (ESR) and peripheral leukocytosis with neutrophilia are the most consistent laboratory findings in SS. The standard therapy is administration of prednisone or prednisolone at an initial dose of 0.5-1.5 mg/kg body weight with a subsequent slow reduction over 2-4 weeks.